Home  »  Industry   »  Analysts suggest bluebird bio Inc. (BLUE) could sp...

Analysts suggest bluebird bio Inc. (BLUE) could spike 38.1% in a year

bluebird bio Inc. (NASDAQ: BLUE) is -10.55% lower on its value in year-to-date trading and has touched a low of $2.87 and a high of $8.58 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The BLUE stock was last observed hovering at around $6.20 in the last trading session, with the day’s loss setting it -0.01% off its average median price target of $8.00 for the next 12 months. It is also 38.1% off the consensus price target high of $10.00 offered by 11 analysts, but current levels are -106.33% lower than the price target low of $3.00 for the same period.

Currently trading at $6.19, the stock is -14.48% and -16.60% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 5.42 million and changing -0.16% at the moment leaves the stock 9.21% off its SMA200. BLUE registered -21.74% loss for a year compared to 6-month gain of 35.15%.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

The stock witnessed a -16.58% loss in the last 1 month and extending the period to 3 months gives it a 3.69%, and is -21.55% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.39% over the week and 7.79% over the month.

bluebird bio Inc. (BLUE) has around 518 employees, a market worth around $490.00M and $5.10M in sales. Distance from 52-week low is 116.06% and -27.86% from its 52-week high. The company has generated returns on investments over the last 12 months (-157.90%).

bluebird bio Inc. (BLUE) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for bluebird bio Inc. (BLUE) is a “Hold”. 11 analysts offering their recommendations for the stock have an average rating of 3.10, where 8 rate it as a Hold and 1 think it is a “Overweight”. 0 of the analysts rate the stock as a “Buy”. 2 analysts have rated the stock as a Sell or Underperform.

bluebird bio Inc. is expected to release its quarterly report on 05/03/2023.The EPS is expected to grow by 9.50% this year.

bluebird bio Inc. (BLUE) Top Institutional Holders

The shares outstanding are 102.92M, and float is at 101.97M with Short Float at 17.89%.

bluebird bio Inc. (BLUE) Insider Activity

A total of 8 insider transactions have happened at bluebird bio Inc. (BLUE) in the last six months, with sales accounting for 5 and purchases happening 3 times. The most recent transaction is an insider sale by Leschly Nick,the company’sDirector. SEC filings show that Leschly Nick sold 4,290 shares of the company’s common stock on Jan 11 at a price of $7.80 per share for a total of $33480.0. Following the sale, the insider now owns 0.28 million shares.

bluebird bio Inc. disclosed in a document filed with the SEC on Jan 11 that Colvin Richard A (Chief Medical Officer) sold a total of 557 shares of the company’s common stock. The trade occurred on Jan 11 and was made at $7.80 per share for $4347.0. Following the transaction, the insider now directly holds 74231.0 shares of the BLUE stock.

Still, SEC filings show that on Jan 11, Obenshain Andrew (President and CEO) disposed off 3,178 shares at an average price of $7.80 for $24802.0. The insider now directly holds 242,690 shares of bluebird bio Inc. (BLUE).

bluebird bio Inc. (BLUE): Who are the competitors?

The company’s main competitors (and peers) include Sangamo Therapeutics Inc. (SGMO) that is trading -41.99% down over the past 12 months and Ionis Pharmaceuticals Inc. (IONS) that is 31.36% higher over the same period. Sanofi (SNY) is -6.14% down on the 1-year trading charts.

Most Popular

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Posts